title: Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid Pseudomonas aeruginosa lung infection.
abstract: The spread of drug-resistant bacterial pathogens is a growing global concern and has prompted an effort to explore potential adjuvant and alternative therapies derived from nature's repertoire of bactericidal proteins and peptides. In humans, the airway surface liquid layer is a rich source of antibiotics, and lysozyme represents one of the most abundant and effective antimicrobial components of airway secretions. Human lysozyme is active against both Gram-positive and Gram-negative bacteria, acting through several mechanisms, including catalytic degradation of cell wall peptidoglycan and subsequent bacterial lysis. In the infected lung, however, lysozyme's dense cationic character can result in sequestration and inhibition by polyanions associated with airway inflammation. As a result, the efficacy of the native enzyme may be compromised in the infected and inflamed lung. To address this limitation, we previously constructed a charge-engineered variant of human lysozyme that was less prone to electrostatic-mediated inhibition in vitro. Here, we employ a murine model to show that this engineered enzyme is superior to wild-type human lysozyme as a treatment for mucoid Pseudomonas aeruginosa lung infections. The engineered enzyme effectively decreases the bacterial burden and reduces markers of inflammation and lung injury. Importantly, we found no evidence of acute toxicity or allergic hypersensitivity upon repeated administration of the engineered biotherapeutic. Thus, the charge-engineered lysozyme represents an interesting therapeutic candidate for P. aeruginosa lung infections.
authors: University of Vermont College of Medicine, Division of Pulmonary and Critical Care Medicine, Burlington, Vermont, USA.
authors: Charlotte C
authors: CC
authors: Teneback
authors: Thomas C
authors: TC
authors: Scanlon
authors: Matthew J
authors: MJ
authors: Wargo
authors: Jenna L
authors: JL
authors: Bement
authors: Karl E
authors: KE
authors: Griswold
authors: Laurie W
authors: LW
authors: Leclair
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D015169:Colony Count, Microbial; D016207:Cytokines / Q000096:biosynthesis / Q000276:immunology; D006025:Glycosaminoglycans / Q000096:biosynthesis / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000517:prevention & control; D008168:Lung / Q000187:drug effects* / Q000382:microbiology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009113:Muramidase / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology*; D015202:Protein Engineering; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000254:growth & development; D055672:Static Electricity
chemical_list: D000900:Anti-Bacterial Agents; D016207:Cytokines; D006025:Glycosaminoglycans; C046129:mucoid exopolysaccharide (P aeruginosa); D009113:Muramidase
references: J Bacteriol. 2005 Jul;187(14):4908-20
references: 15995206
references: Am J Respir Crit Care Med. 2004 Feb 15;169(4):454-8
references: 14617511
references: J Biosci. 2010 Mar;35(1):127-60
references: 20413917
references: J Immunol. 2000 Nov 15;165(10):5760-6
references: 11067934
references: Science. 2008 Jul 18;321(5887):356-61
references: 18635788
references: J Immunol. 2006 Jul 1;177(1):519-26
references: 16785549
references: Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8225-9
references: 8710851
references: Am J Respir Cell Mol Biol. 2003 Jun;28(6):738-45
references: 12600826
references: Nat Rev Microbiol. 2006 Jan;4(1):36-45
references: 16357859
references: Antimicrob Agents Chemother. 2005 Aug;49(8):3382-6
references: 16048951
references: FEBS Lett. 2001 Sep 28;506(1):27-32
references: 11591365
references: Biochem J. 2009 Apr 1;419(1):193-200
references: 19105793
references: ACS Chem Biol. 2010 Sep 17;5(9):809-18
references: 20604527
references: Clin Microbiol Rev. 2003 Oct;16(4):673-87
references: 14557293
references: Clin Chest Med. 2005 Mar;26(1):57-64
references: 15802166
references: Pediatr Pulmonol. 2009 Apr;44(4):402-9
references: 19283840
references: Chest. 2005 Oct;128(4):2336-46
references: 16236892
references: Infect Immun. 1990 Oct;58(10):3363-8
references: 2401567
references: Nat Rev Microbiol. 2007 Sep;5(9):727-40
references: 17703227
references: Antimicrob Agents Chemother. 2003 Jan;47(1):317-23
references: 12499208
references: Antimicrob Agents Chemother. 2013 Jan;57(1):137-45
references: 23070175
references: J Biotechnol. 2013 Mar 10;164(1):1-8
references: 23220215
references: Transgenic Res. 2005 Oct;14(5):583-92
references: 16245149
references: PLoS One. 2011 Mar 07;6(3):e16788
references: 21408218
references: Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):15994-9
references: 17911256
references: Curr Opin Crit Care. 2007 Feb;13(1):45-50
references: 17198048
references: Exp Lung Res. 2010 Mar;36(2):94-100
references: 20205599
references: JAMA. 1999 Jan 6;281(1):61-6
references: 9892452
references: Chest. 2006 Jul;130(1):251-60
references: 16840410
references: APMIS. 2006 Feb;114(2):131-8
references: 16519750
references: PLoS Med. 2006 Feb;3(2):e76
references: 16401173
references: Exp Lung Res. 2011 Nov;37(9):536-41
references: 21967196
references: Curr Opin Pulm Med. 2003 Nov;9(6):509-15
references: 14534404
references: Infect Immun. 1981 Jul;33(1):142-8
references: 6790439
references: J Antimicrob Chemother. 2012 Nov;67(11):2673-81
references: 22843834
references: Expert Rev Anti Infect Ther. 2003 Dec;1(4):609-18
references: 15482158